Citigroup Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $35

Benzinga Newsdesk www.benzinga.com Positive 62.3%

Neg 0% Neu 0% Pos 62.3%

Citigroup analyst Yigal Nochomovitz initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $35.